SOURCE: Novo Energies Corporation

March 14, 2012 06:00 ET

Novo Energies Corporation Announces That Dr. Michael Har-Noy Has Been Invited to Be a Guest Speaker at the 11th Annual National Cancer Conference in Thailand

NEW YORK, NY--(Marketwire - Mar 14, 2012) - Novo Energies Corporation ("Novo") (OTCBB: NVNC) today announced that Dr. Michael Har-Noy, the Founder and Chief Executive Officer of Immunovative Therapies, Ltd., ("Immunovative") has been invited to be a Guest Speaker at the Thailand 11th National Cancer Conference which is held on the Auspicious Occasion of His Majesty the King's 84th Birthday Anniversary. The conference is to be held on March 14-16, 2012 in Bangkok, Thailand. The Conference is sponsored by the National Cancer Institute of Thailand and aims to raise cancer awareness under the theme of "Bridging Cancer Research to Optimized Cancer Care and Control." The participants include medical doctors, nurses, physicians, research scientists, pharmacists, public health administrators and personnel throughout the country and more than 700 participants are expected to attend the event.

The Conference invited Dr. Har-Noy to be the Guest Speaker on the Plenary Lecture 4 "Update on Tumor Immunology Concepts and Application to the Design of Effective Immunotherapies for Cancer" on Friday, March 16th, 2012, based upon his expertise and worldwide reputation in Cancer Immunology.

Dr. Michael Har-Noy stated, "I am extremely honored to be invited to present at such a prestigious conference. Immunovative has established strong collaborations with the National Cancer Institute of Thailand and with two experienced clinical investigators, Dr. Wirote Lausoontornsiri, MD and Dr. Somjin Chindavijak, MD. We are currently in the late stages of planning to launch a Phase II/III randomized, controlled clinical trial in anthracycline-taxane resistant metastatic breast cancer for our lead AlloStim product candidate and a Phase I/II clinical trial for recurrent head and neck cancer for our personalized anti-cancer vaccine product candidate, AlloVaxat the National Cancer Institute of Thailand."

About the National Cancer Institute (Thailand): The National Cancer Institute (NCI) of Thailand, located in Bangkok, is one of the major comprehensive cancer centers in Asia and was originally established as a Research Institute on the 10th December 1968, by his Majesty the King of Thailand. Demand soon required addition of a cancer hospital and a totally new center outside of Bangkok was also built, encompassing a hospice with a basic research center. Subsequently, a further 6 centers were set up in outside regions to allow coordination of efforts on a nationwide basis. Please visit the Institute's website at The program and schedule for the Conference can be found at: and

About Immunovative Therapies, Ltd.: Immunovative Therapies, Ltd. ("Immunovative") is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. Immunovative was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Immunovative is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer. Immunovative has two experimental immunotherapy products for the treatment of cancer in clinical development: AlloStim™ and AlloVax™ covered by Immunovative's 10 U.S. patents granted, 15 U.S. patents pending and 26 corresponding applications pending internationally. Please visit Immunovative's website at:

About Novo Energies Corporation: On December 15, 2011, Novo Energies Corporation ("Novo") signed an exclusive License Agreement (the "License Agreement") with Immunovative. Under the terms of the License Agreement, Novo has been granted an exclusive, worldwide license to commercialize any products covered under Immunovative 's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including. Novo is in the process of transforming into the cancer therapy area and intends to institute a name and symbol change to better reflect the new direction of the Company.

DISCLAIMER Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Novo's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Novo has little or no control. Such forward-looking statements are made only as of the date of this release, and Novo assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in Novo's Form 10-K for its fiscal year ended March 31, 2011, and other documents filed from time to time by Novo with the Securities and Exchange Commission.

Contact Information

  • For more information, please contact:
    Mr. Antonio Treminio
    Chairman & Chief Executive Officer
    Novo Energies Corporation
    New York: +1-212-315-9705
    Montreal: +1-514-840-3697
    Email: Email Contact

    Dr. Michael Har-Noy
    Founder & Chief Executive Officer
    Immunovative Therapies, Ltd.
    Israel Tel: +972-2-6506288
    US Tel: +1-760-444-9040
    Email: Email Contact